The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial in LGS in second half of this year. ZX008 is a low-dose fenfluramine liquid solution that is also under investigation for Dravet syndrome, for which it has also been granted orphan drug designation.Next Story
Low-Dose Fenfluramine Granted Orphan Status for LGS
Tuesday, June 27, 2017
You must be logged in to leave a comment.